Source: Pluristem Life Systems, Inc.
Posted: July 23, 2007 8:00 am ET
Summary:
Pluristem Life Systems, Inc., a bio-therapeutics Company dedicated to the commercialization of products for a variety of malignant, degenerative and auto-immune indications, announced today that favorable results have been obtained in pre-clinical testing using the Company's proprietary PLX cells (placenta derived mesenchymal stem cells) to treat limb ischemia..."
